Over 30 Years Experience
Expert In Vivo Efficacy Testing for a wide variety of human diseases

Browse Our Services by Category:

WBI’s specialized In Vivo Efficacy Testing Services cover four major disease categories – Autoimmune and Inflammatory Diseases (including a separate category for Rheumatoid Arthritis), Cancer, Bacterial Infection and Pain. Complementary services include Pharmacokinetics (PK), Toxicity and Support Services.

Multiple Sclerosis (MS)

Rheumatoid Arthritis


Inflammatory Bowel Disease (IBD)

Dermatitis (Contact)


  • SLE Mouse Model - where disease development is followed by injection of pristane leading to an inflammatory process resulting in lupus-specific autoantibodies, immune complex deposition and glomerulonephritis.





  • IMQ Psoriasis Model - designed to rapidly assess therapeutic efficacy within a few hours by measurement of serum amylase activity.


  • STZ-induced Diabetes (rat) - a Streptozocin-induced SD rat model useful for studying the effectiveness of potential anti-diabetic agents.

General Inflammation Assessment

  • Carrageenan Paw Edema (CPE) - a rapid one-day screen for anti-inflammatory efficacy measured through paw edema.
  • LPS/Cytokine response - a model which evaluates the efficacy of inhibition of endotoxin-induced inflammation by measurement of cytokine release.

WBI has long experience testing therapeutic and prophylactic agents in well-established in vivo models for Rheumatoid Arthritis (RA) including:

  • Collagen-induced (CIA) Arthritis, - the “standard” animal model for evaluation of anti-arthritic activity; an excellent model for RA and hence for early prophylactic or therapeutic intervention in the disease.
  • Adjuvant-induced (AIA) Arthritis  - an economical in vivo screen and one of the longest established animal models for testing arthritis treatments
  • Air Pouch Carrageenan  - through differential cell analysis of inflammatory exudates this unique  model identifies possible cell types suppressed by the test compound and hence potential underlying mechanism of drug action.
  • Air Pouch Zymosan - a model considered useful for quantitative measurements and biochemical analysis of the inflammatory process in which complement activation plays an important role. 
  • Pristane-induced (PIA) Arthritis - that most closely simulates the autoimmune RA condition in humans
  • Ovalbumin-induced (OIA) Arthritis - a large animal (rabbit) model for RA with the advantage of synovial fluid measures at convenient volumes.
  • Streptococcal Cell Wall PG-PS 10S (SCW) - allowing evaluation of compound efficacy for acute and/ or chronic inflammatory phases.
  • Two species Test (CIA/OIA Combo) – Combo-testing of CIA in rodents and OIA in rabbits is offered due to the importance of results from more than one species in predicting efficacy for treatment of humans.


WBI Human Cancer Cell Lines are available for a wide variety of cancers.

WBI offers Xenograft, Orthotopic and Syngeneic Models in both mice and rats (infusion).

Models include: Breast Cancer, Prostate Cancer, Melanoma, Myeloma, Lymphoma, Liver Cancer, Lung CancerKidney Cancer, Colon CancerBrain Cancer and Head and Neck Cancers. WBI scientists provide expert guidance in dosing and routes of drug administration.


WBI offers a number of bacterial challenge models including Listeria monocytogenes and Methicillin Resistant Staph Aureus (MRSA).

WBI offers basic in vivo models for thermal and mechanical pain responses which may be combined with inflammation models to provide information on analgesic activity in inflamed tissue; and the Formalin Test (Chemical Sensitivity), the most predictive of models for acute pain.

  • Pharmacokinetics (PK) - fast-turnaround and low cost studies with clear and frequent client communications. Start-up within 48 hours of order. Rodents, guinea pigs and rabbits.
  • Toxicity – MTD Studies - including expert interpretation of results.

WBI Services to complement disease model efficacy studies include:

Formulations – to develop a bioavailable, stable and optimal dosage form for a specific administration route.

In Vitro Compound Screening for early screening of test materials

Other services including: Tissue Culture, Bacterial Culture, Cardiovascular Screen Services, Clinical Chemistry, Cell Counts and Differentials, Necropsy and Histology.

Washington Biotechnology, Inc. (WBI) is a leading In Vivo Services Contract Research Organization (CRO) for drug development.

For over 25 years we have provided our global biopharmaceutical clients with rapidly scheduled, accurate and cost-effective efficacy testing services.

Our clients drive innovation. We feel privileged to serve them in advancing treatments for human disease. In our role as CRO Partner, we are committed to the highest standards of science and project management.

Learn More